NanoRX Publishes New Research Paper: Metadichol® an anti-viral agent against SARS-COV-2

CHAPPAQUA, N.Y. - Rezul -- Metadichol®, a nano lipid formulation of long chain alcohols, has been shown in vitro studies to be an anti-viral for SARS-COV-2 (the COVID-19 virus) and it does so by blocking the cell entry points for SARS-COV-2. The receptor ACE2 is used by the virus for entry and the serine protease TMPRSS2 for S protein priming.  It inhibits both ACE2 and TMPRSS2. An anti-viral assay against the virus using CACO2 cells showed that it had an EC90 of 0.16 µg/ml, which means it effectively eliminates the virus at a very low concentration.

Metadichol® inhibits TMPRSS2 (EC50 of 96 ng/ml). It is 270 times more potent than another another well known inhibitor Camostat mesylate, which has EC50 of (26000 ng/ml). Metadichol is also a moderate inhibitor of ACE2 with an EC50 of 31 µg/ml. Moderate inhibition of ACE2 allows it to perform its key functions in the body, yet fend off SARS-COV-2 entry to the cell. ACE2 lowers blood pressure, regulates intestinal neutral amino acid transport. ACE2 expression and function is increasingly recognized as a potential therapeutic strategy in hypertension and cardiovascular disease, diabetes, lung injury, and fibrotic disorders.

More on Rezul News

• $57 Billion U.S. Marine Industry Presents Major Growth Opportunity for Newly Public Off The Hook Yacht Sales, Inc. (N Y S E: OTH)
• Reozom Announces Partnership Model
• David Weekley Homes' ATL Division Smoked Last Year's Numbers During 2025 Thanksgiving Food Drive
• Dr. Alexander Eastman Returns to Suburban Hospital to Deliver Keynote on Crisis Leadership
• Scoop Social Co.'s Mobile Dessert Truck Business Offer A Lifestyle Of Flavor, Fun, and Freedom

Metadichol, by binding to the Vitamin D receptor (VDR), acts on proteases like Furin and Adam-17, which activate the S-protein spikes for viral spread and pathogenesis in the infected hosts. In Malaria, CD147,  also known as Basigin, is used by parasites to gain entry into the cell. Recent publications suggest that it also can be used as a point of entry by the SARS-COV-2 virus. Our previous work (US patent 9,006,292) showed that Metadichol is also potent against Malarial parasites and, by association, CD147. All these results and others are documented in our recent publication available at  (https://www.researchsquare.com/article/rs-34021/v1)

A pilot study (outside the USA) on five COVID-19 patients with minor symptoms showed the absence of a virus after 2-4 days of Metadichol @ 20 mg per day. To validate this further, we have initiated a study in collaboration with government agencies. The initial study of 30 patients showed 75% of the patients cleared of the SARS-COV-2 virus after 4 days of treatment - see http://nanorxeurope.com/Documents/India-hospital-letter.pdf.

More on Rezul News

• Own 327 Acres of American Prime Real Estate with 2 Miles Waterfront Worth In Millions for Just $7 — Worldwide Raffle Launched
• Lakefront Acreage in Longwood's Ravensbrook Community Hits the Market
• Monika Balayan Elected Fellow of the Royal Society of Arts (FRSA)
• Elevate Sales Kick Off Announces National Event for Property Management Growth in 2026
• We're Winning: Historic Plunge in Overdose Deaths Marks Stunning Reversal in America's Drug Crisis

Metadichol is a safe, non-toxic product made from renewable sources and commercially available with no reported side effects. This unique property allows for the use of Metadichol in a situation that exists today and also to prevent future occurrence of SARS-COV-2 and other infections, and use of it worldwide would allow normal human activity everywhere.

Patent details and publications can be found at https://www.researchgate.net/profile/Palayakotai_Raghavan.
Metadichol, marketed as Nano Soma can be found at www.thenanosoma.com and http://www.nanosoma.net, whilst Nano-Ojas can be found at www.nanoojas.net and Metadichol at www.gen100.com.
Metadichol is available as an oral or topical spray, a topical (or oral) gel and a face cream.

For further information contact:
media_relations@nanorxeurope.com
+1 443 769 1752 (USA)
+44 1212 840 929 (UK)
+61 3 9021 6920 (AUSTRALIA)
+31 30 808 045 (HOLLAND)
+91 98194 85080 (INDIA)